01.10.2012 22:30
Bewerten
 (0)

Elan Announces Redemption of Its Senior Notes Due 2016

Elan Corporation, plc ("Elan”) (NYSE: ELN) announced today that it will redeem all of the Senior Notes due 2016 issued on October 2, 2009 (the "2009 Notes”) and Senior Notes due 2016 issued on August 17, 2010 (the "2010 Notes” and, together with the 2009 Notes, the "Notes”) of its wholly owned subsidiaries, Elan Finance public limited company and Elan Finance Corp. (the "Co-Issuers”), that remain outstanding following the completion of the Co-Issuers’ previously announced tender offer to purchase any and all of the outstanding Notes (the "Tender Offer”). The Tender Offer is made pursuant to an Offer to Purchase and Consent Solicitation Statement (the "Offer to Purchase and Consent Solicitation Statement”), dated September 24, 2012, and will expire at 11:59 p.m., Eastern Time, on October 22, 2012, unless the Tender Offer is extended or earlier terminated (the "Expiration Date”). Notes in an aggregate principal amount of $624.5 million are currently outstanding.

The Notes are redeemable at the Co-Issuers’ option at a redemption price equal to 108.750% of the outstanding principal amount (i.e., $1,087.50 per $1,000 principal amount of the Notes), plus an amount equal to $3.89 per $1,000 principal amount, which represents the accrued but unpaid interest from October 15, 2012, the most recent interest payment date of the Notes, to October 31, 2012. The redemption is expected to occur on October 31, 2012.

Under the terms of the Tender Offer, holders of the Notes who validly tender and do not withdraw their Notes prior to 11:59 p.m., Eastern Time, on October 5, 2012 (as such time and date may be extended, the "Consent Payment Deadline”) and whose Notes are accepted for purchase, will receive the "Total Consideration,” which is equal to (i) $1,053.34 per $1,000.00 principal amount of Notes validly tendered (the "Tender Offer Consideration”) plus (ii) a consent payment of $40.00 per $1,000.00 principal amount of Notes validly tendered. Holders of Notes who validly tender their Notes after the Consent Payment Deadline but on or before the Expiration Date, and whose Notes are accepted for purchase, will receive only the Tender Offer Consideration. In addition to the Total Consideration or the Tender Offer Consideration, holders whose Notes are accepted in the Tender Offer will receive accrued and unpaid interest from and including the most recent interest payment date, and up to, but excluding, the applicable settlement date.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the Company, please visit www.elan.com.

Safe Harbor/Forward-Looking Statements

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.

The information contained in this press release is not for publication or distribution in Canada, Australia or Japan and does not constitute an offer of securities for sale in Canada, Australia or Japan.

In the United Kingdom, this press release is directed only at (i) Persons who have professional experience in matters relating to investments falling within Article 19(1) of The Financial Services And Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (ii) High Net Worth Entities falling within Article 49(2) of The Order and (iii) persons to whom it would otherwise be lawful to distribute it (all such persons together being referred to as "Relevant Persons").

In addition, if and to the extent that this press release is communicated in any EEA member state that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any member state, the "Prospectus Directive”), this press release is only addressed to and directed at persons in that member state who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that member state. This press release does not constitute a prospectus within the meaning of the Prospectus Directive. This press release constitutes an advertisement for the purposes of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (as amended).

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the completion of the Tender Offer and Consent Solicitation. You can identify these statements by the fact that they use words such as "expect”, "estimate”, and "intend” and other words and terms of similar meaning in connection with any discussion of future events. Factors that could affect whether the Tender Offer and Consent Solicitation is completed include, among other things, uncertainties related to corporate debt securities generally, the securities of biotechnology companies generally and Elan’s debt securities in particular. A further list and description of risks, uncertainties and other matters can be found in Elan’s Annual Report on Form 20-F for the fiscal year ended December 31, 2011 and in its Reports of Foreign Issuer on Form 6-K furnished to the Securities and Exchange Commission. Elan assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

SOURCE: Elan Corporation, plc:

Artikel empfehlen?

Nachrichten zu Elan Corporation PLC (spons. ADRs)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?
Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen
Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen
vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden
Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

RSS Feed

Analysen zu Elan Corporation PLC (spons. ADRs)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
08.08.2012Elan neutralExane-BNP Paribas SA
02.08.2012Elan outperformRBC Capital Markets
26.07.2012Elan neutralExane-BNP Paribas SA
26.07.2012Elan neutralUBS AG
23.07.2012Elan outperformRBC Capital Markets
02.08.2012Elan outperformRBC Capital Markets
23.07.2012Elan outperformRBC Capital Markets
22.06.2012Elan outperformRBC Capital Markets
14.06.2012Elan buyJefferies & Company Inc.
28.03.2012Elan outperformRBC Capital Markets
08.08.2012Elan neutralExane-BNP Paribas SA
26.07.2012Elan neutralExane-BNP Paribas SA
26.07.2012Elan neutralUBS AG
27.04.2012Elan neutralExane-BNP Paribas SA
13.01.2011Elan neutralUBS AG
21.07.2010Elan reduceGoodbody Stockbrokers
16.07.2010Elan "reduce"Goodbody Stockbrokers
02.08.2006Update Elan Corporation plc (Spons. ADRs): UnderpePiper Jaffray
06.06.2006Update Elan Corporation plc (Spons. ADRs): UnderpePiper Jaffray
20.01.2006Update Elan Corporation plc (Spons. ADRs): UnderweLehman Brothers
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Elan Corporation PLC (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen
Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"

mehr
Für den Live-Chat können Sie sich mit Ihrem finanzen.net-, Facebook- oder Twitter Account anmelden. Um immer die neusten Beiträge zu sehen, stellen Sie bitte "Neuesten" ein.

Private Krankenversicherung Tarifvergleich

Anzeige

Meistgelesene Elan News

Keine Nachrichten gefunden.
Weitere Elan News

Elan Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX leicht im Minus -- Dow verliert leicht -- Apple verkauft über zehn Millionen neue iPhones am ersten Wochenende -- Ultrasonic-Aktie gewinnt rund 150 Prozent -- Merck, Siemens, ThyssenKrupp im Fokus

Air France geht auf streikende Piloten zu - doch diese lehnen ab. Alibaba bestätigt Rekord bei Börsengang. Total kappt Produktionsziele und kürzt Ausgaben. Sulzer beendet Gespräche mit Dresser-Rand. Bundesbankchef Weidmann sieht EZB auf gefährlichem Kurs. Merck KGaA kauft Sigma-Aldrich für 17 Milliarden Dollar.
Diese Aktien sind auf den Kauflisten der Experten

Welche US-Aktien könnten zum Jahresende hin steigen?

Die 5 beliebtesten Top-Rankings

Welches Unternehmen erzielte bislang das größte Emissions- volumen?

Welche Darsteller verdienen am meisten?

Diese Models verdienten 2014 am meisten

In welchen Ländern kostet der Big Mac wie viel?

Die Fluglinien mit den zufriedensten Passagieren

mehr Top Rankings
Die umstrittenen Maut-Pläne werden möglicherweise nachgebessert. So soll die Abgabe für Pkw wohl doch nur auf Autobahnen und Bundesstraßen erhoben werden. Wie stehen Sie zu dem Thema.